Pfizer Inc’s chief executive said on Tuesday that almost 250,000 courses of the drugmaker’s oral antiviral COVID-19 treatment Paxlovid were being administered per week as cases surged in the United States.
Speaking at the Cantor Fitzgerald Annual Healthcare Conference, Chief Executive Officer Albert Bourla said the company is still uncertain about when Paxlovid, which is currently being distributed by the government, will receive approval to be sold in the U.S. commercial market.
Paxlovid, taken for five days beginning shortly after onset of symptoms, is used to treat adults at high risk of hospitalizations and deaths from COVID-19.
Bourla, however, said Pfizer is ready to supply its COVID-19 vaccines with a smooth transition to the commercial market.
“There is enough product that has been already manufactured and we keep manufacturing,” Bourla said. “We are very confident that the market will be very well supplied.”
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.